The price of Teva- Pharmaceutical Industries Ltd. ADR (NYSE:TEVA) shares last traded on Wall Street rose 3.01% to $17.77.
TEVA stock price is now 12.58% away from the 50-day moving average and 1.39% away from the 200-day moving average. The market capitalization of the company currently stands at $20.36B.
With the price target of $24, Goldman recently initiated with Buy rating for Teva- Pharmaceutical Industries Ltd. ADR (NYSE: TEVA). On May 28, 2025, Truist recently initiated its ‘Buy’ rating on the stock quoting a target price of $25, while ‘JP Morgan’ rates the stock as ‘Overweight’
In other news, Shields Matthew, EVP, Global Operations sold 6,206 shares of the company’s stock on Jun 03 ’25. The stock was sold for $105,628 at an average price of $17.02. Upon completion of the transaction, the EVP, Global Operations now directly owns 9,989 shares in the company, valued at $0.18 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jun 03 ’25, Officer Shields Matthew bought 6,206 shares of the business’s stock. A total of $105,628 was incurred on buying the stock at an average price of $17.02. A total of 0.01% of the company’s stock is owned by insiders.
During the past 12 months, Teva- Pharmaceutical Industries Ltd. ADR has had a low of $12.47 and a high of $22.80. As of last week, the company has a debt-to-equity ratio of 2.71, a current ratio of 1.03, and a quick ratio of 0.74.
The net profit margin was -7.76% and return on equity was -18.98% for TEVA. The company reported revenue of $3.89 billion for the quarter, compared to $3.82 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 1.89 percent. For the current quarter, analysts expect TEVA to generate $4.34B in revenue.
